PAR 7.69% 21.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-1521

  1. 1,226 Posts.
    lightbulb Created with Sketch. 177


    Targeting the Wnt Pathway Fails in OA— In a phase IIa trial of knee osteoarthritis, lorecivivint failed to meet the primary pain endpoint:

    https://www.medpagetoday.com/rheumatology/arthritis/86677

    May 26, 2020
    The Wnt pathway modulator lorecivivint failed to meet the primary endpoint in a phase IIa study for knee osteoarthritis (OA), but showed promise in certain patient subgroups, researchers reported.

    On the primary endpoint, which was improvement in pain on the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index, no dose of intra-articular lorecivivint (0.03 mg, 0.07 mg, or 0.23 mg) showed statistically significant differences from placebo at week 13, according to Yusuf Yazici, MD, of NYU Langone Medical Center in New York City, and colleagues. Yazici is also chief medical officer of Samumed, the study sponsor.

    However, in a post-hoc exploratory analysis of a subgroup of patients who had unilateral knee pain, patients receiving the 0.07-mg dose had significant improvements at week 52 on WOMAC pain scores, with a between-group difference of -8.73 (95% CI -17.44 to -0.03, P=0.049), and also on function scores, with a between-group difference of -10.26 (95% CI -19.82 to -0.69, P=0.036), they reported online in Arthritis & Rheumatology.

    Nonetheless, "the study was negative," commented David T. Felson, MD, of Boston University School of Medicine, who was not involved in the study. "They did some secondary analyses where they tried to find a positive subgroup, but those usually aren't very robust in terms of findings," he said."The results are discouraging," Felson told MedPage Today.

    Sorry..oxxa, didn't see your link.




    Last edited by edski1: 29/04/21
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.